A novel drug screening approach to identify new drug candidates for the treatment of Duchenne muscular dystrophy


Duchenne muscular dystrophy (DMD) is the most common type of muscular dystrophy. DMD is a very severe disorder presenting with rapidly progressing muscle wasting and premature death. No current treatment is available and drugs improving the course of the disease are limited and with various side effects. The aim of this work is to develop a drug screening assay to find new drug candidates for DMD. A high throughput screening test was developed using a unique in vitro differentiation protocol recapitulating key signaling events in skeletal muscle development.


Leave A Reply